Home › Funds › Cormorant Asset Management, LP › PCVX

Cormorant Asset Management, LP position in PCVX

VAXCYTE INC · Health Care

Cormorant Asset Management, LP reported holding 50,000 shares of PCVX (VAXCYTE INC) in its Q2 2026 13F filing — a position valued at US$2.9M, representing 0.15% of its reported portfolio and ranking #48 among its reported holdings. Cormorant Asset Management, LP has disclosed PCVX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)50.00K sh
Reported value held$2.91M
Portfolio Weight0.15%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Cormorant Asset Management, LP's PCVX position evolved

Cormorant Asset Management, LP first disclosed a stake in PCVX in Q3 2023 at 665,000 shares (US$33.9M). The position peaked in Q3 2024 at 1,000,000 shares, worth US$114.3M. Across 12 filings, Cormorant Asset Management, LP increased the stake 2 time(s), trimmed it 6 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 50,000 shares valued at US$2.9M — a reduction of -50,000 shares quarter over quarter.. Notable position changes include a 61% increase in Q2 2024 (shares rose 51% over the following quarter), a 58% trim in Q4 2024 (shares fell 54% over the following quarter), a 59% trim in Q1 2025 (shares fell 14% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 665.00K $33.90M New
Q4 2023 665.00K $41.76M Hold
Q1 2024 685.00K $46.79M Add
Q2 2024 1.10M $83.06M Add
Q3 2024 1.00M $114.27M Reduce
Q4 2024 425.00K $34.79M Reduce
Q1 2025 175.00K $6.61M Reduce
Q2 2025 175.00K $5.69M Hold
Q3 2025 175.00K $6.30M Hold
Q4 2025 125.00K $5.77M Reduce
Q1 2026 100.00K $5.81M Reduce
Q2 2026 50.00K $2.91M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PCVX and 13F data

PCVX (VAXCYTE INC) is a Health Care company. 36 other funds we track also report a position in PCVX — the largest reported positions include Jupiter Topco LLC (US$1.04B), Janus Henderson Group (US$960.2M), T. Rowe Price Investment Management, Inc. (US$709.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PCVX

All PCVX fund holders →

FAQ

How long has Cormorant Asset Management, LP held PCVX?

Cormorant Asset Management, LP has disclosed PCVX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Cormorant Asset Management, LP's current position in PCVX?

As of Q2 2026, Cormorant Asset Management, LP holds 50.00K shares of PCVX (VAXCYTE INC), valued at $2.91M, representing 0.15% of its reported portfolio and ranking #48.

Has Cormorant Asset Management, LP been buying or selling PCVX?

In the latest 13F filing (Q2 2026), Cormorant Asset Management, LP reduced its position in PCVX. The position peaked in Q3 2024 at 1.00M shares.

Which other funds hold PCVX?

Other major institutional holders of PCVX include Jupiter Topco LLC, Janus Henderson Group, T. Rowe Price Investment Management, Inc., among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.